Medicine and Dentistry
Prostate Cancer
100%
Neoplasm
33%
Positron Emission Tomography-Computed Tomography
31%
Fluorine-18
30%
Androgen Deprivation Therapy
24%
Prostate Specific Membrane Antigen
23%
Clear Cell Renal Cell Carcinoma
22%
Bladder Cancer
21%
Metastatic Carcinoma
19%
Castration Resistant Prostate Cancer
18%
Non Muscle Invasive Bladder Cancer
17%
Recurrent Disease
16%
Transitional Cell Carcinoma
14%
Urinary System
14%
Prostatectomy
13%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
50%
Androgen
23%
Castration Resistant Prostate Cancer
18%
Neoplasm
16%
Bladder Cancer
13%
Cancer Registry
12%
Fluorine 18
12%
Overall Survival
12%
Muscle Invasive Bladder Cancer
11%
Polyethylene Terephthalate
9%
Non Muscle Invasive Bladder Cancer
9%
Recurrent Disease
8%
Estetrol
7%
Renal Cell Carcinoma
6%
Prostate Specific Antigen
6%
Keyphrases
Prostate Cancer
22%
Androgen Deprivation Therapy
17%
Non-muscle Invasive Bladder Cancer (NMIBC)
13%
Prostate Cancer Patients
12%
18F-DCFPyL
11%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
10%
Positron Emission Tomography-computed Tomography (PET-CT)
9%
Primary Prostate Cancer
9%
Mitomycin C
9%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
9%
Confidence Interval
8%
Prostate-specific Antigen
8%
Recurrence Rate
8%
Renal Cell Carcinoma
7%
Prostate-specific Membrane Antigen Positron Emission Tomography
7%